HFNC Versus Microstream Advance Nasal Cannula for Oxygenation During ERCP
NCT: NCT07611903 · NOT_YET_RECRUITING
Brief Summary
Endoscopic retrograde cholangiopancreatography (ERCP) procedures are commonly performed under deep sedation and are associated with a risk of hypoxemia, particularly in prone or semi-prone positions. High-flow nasal cannula (HFNC) therapy may improve oxygenation by delivering heated and humidified oxygen at high flow rates, while the Microstream Advance nasal cannula provides simultaneous nasal oxygen delivery and oral oxygen insufflation. This prospective randomized study aims to compare the effectiveness of HFNC and Microstream Advance nasal cannula in maintaining oxygenation during ERCP procedures. Patients undergoing ERCP will be randomized into two groups receiving either HFNC or Microstream Advance nasal cannula oxygen support during sedation. The primary outcomes are the incidence of desaturation and oxygen reserve index (ORi) measurements during the procedure. Secondary outcomes include time to achieve target ORi levels, respiratory complications, and procedure-related adverse events.
Frequently Asked Questions
What is HFNC Versus Microstream Advance Nasal Cannula for Oxygenation During ERCP?
HFNC Versus Microstream Advance Nasal Cannula for Oxygenation During ERCP is a clinical trial registered under NCT07611903. Current status: NOT_YET_RECRUITING.
What is the status of NCT07611903?
The current status of NCT07611903 (HFNC Versus Microstream Advance Nasal Cannula for Oxygenation During ERCP) is: NOT_YET_RECRUITING.
When did HFNC Versus Microstream Advance Nasal Cannula for Oxygenation During ERCP start?
HFNC Versus Microstream Advance Nasal Cannula for Oxygenation During ERCP started on 2026-06-29.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.